|
NUP153 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.26352270260577E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.660116488722E-12 |
| Normal-vs-Stage2 |
2.40419906205602E-11 |
| Normal-vs-Stage3 |
3.78586051397178E-13 |
| Normal-vs-Stage4 |
1.75570669114222E-12 |
| Stage1-vs-Stage2 |
8.560000E-01 |
| Stage1-vs-Stage3 |
3.244600E-01 |
| Stage1-vs-Stage4 |
1.522400E-01 |
| Stage2-vs-Stage3 |
6.215000E-01 |
| Stage2-vs-Stage4 |
3.022200E-01 |
| Stage3-vs-Stage4 |
5.576000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.02962083303737E-12 |
| Normal-vs-AfricanAmerican |
3.43879999997743E-06 |
| Normal-vs-Asian |
8.72379946059709E-12 |
| Caucasian-vs-AfricanAmerican |
3.143800E-01 |
| Caucasian-vs-Asian |
7.496800E-01 |
| AfricanAmerican-vs-Asian |
2.820800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.20068407941199E-12 |
| Normal-vs-Female |
2.50455212125189E-12 |
| Male-vs-Female |
6.519400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
5.22215604092935E-12 |
| Normal-vs-Age(41-60Yrs) |
1.8908208332391E-12 |
| Normal-vs-Age(61-80Yrs) |
2.17181828077173E-12 |
| Normal-vs-Age(81-100Yrs) |
3.258300E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.500200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.570200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.704000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.512600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.359600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.057400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
7.575700E-02 |
| Classical-VS-Follicular |
1.239920E-02 |
| Classical-VS-Other |
1.924800E-01 |
| Classical-VS-Normal |
3.9375946947473E-11 |
| Tall-VS-Follicular |
8.937200E-01 |
| Tall-VS-Other |
6.793600E-01 |
| Tall-VS-Normal |
5.78581627053154E-12 |
| Follicular-VS-Other |
6.519400E-01 |
| Follicular-VS-Normal |
3.18745030369882E-13 |
| Other-VS-Normal |
2.360300E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.81277215460796E-12 |
| Normal-vs-N1 |
2.05380157325408E-12 |
| N0-vs-N1 |
5.635600E-01 |
|
|
